Pipeline

The development programs of the company include radiopharmaceutical drug product candidates for treatment of various solid cancers. The technology platform is focused on the use of alpha-emitting radionuclides as therapeutic payload.

The company’s lead candidate Radspherin is currently in clinical development in two indications; peritoneal metastasis from ovarian and colorectal cancer but is also relevant for treating peritoneal metastasis from other cancer types and potentially metastatic cancer in other body cavities. 

The company has developed the proprietary antibody OI-1 which targets the protein tyrosine kinase 7 (PTK7). As a pseudokinase lacking catalytic activity in its intracellular domain, PTK7 is insensitive to traditional tyrosine kinase inhibitors, making it a promising target for radionuclide- or drug delivery using antibodies. This asset is available for partnering or out-licensing.

 

Partnering

At Oncoinvent we aspire to transform cancer care through direct alpha therapy. We are actively seeking strategic partnerships to advance our drug development and maximize the potential of our pipeline . Complementing our pipeline, our highly skilled and experienced organization, coupled with state-of-the-art facilities, positions us as a valuable collaborator in the radiopharmaceutical space. We welcome discussions with potential partners that share our commitment in making a difference for cancer patients through innovative therapies. Please contact us to explore how we can create value and drive meaningful impact together. 

 

 

About

Management

Board of Directors

Radspherin®

Pipeline

Publications

News

Events

Newsletter subscription

Reports and presentations

The Share

IR Contact

+47 22 18 33 05

Oncoinvent ASA Gullhaugveien 7 0484 Oslo Norway

© Oncoinvent. All rights reserved. Design by Anagram Design AS

Øystein Soug

Chief Executive Officer

soug@oncoinvent.com

Oystein Soug has over 15 years of experience in biotechnology, holding several management positions. Most recently, Mr. Soug was CEO of Arxx Therapeutics, where he led the company to initiate the clinical programme and was responsible for the merger with Dutch pharma company Oxitope Pharma to create Calluna Pharma. Prior to Arxx, he served as CFO and then CEO of Targovax, an Oslo listed biotechnology company, which went public during Mr. Soug’s tenure. Mr. Soug started his career in biotech as CFO of Oslo-listed radiopharmaceutical company Algeta. During this period, the company conducted a successful phase 3 trial, launched its radium-223 based prostate cancer drug Xofigo® and out-licensed the drug. Mr. Soug co-led the sale of the company to Bayer in 2014.  

Mr. Soug holds an MSc in Economics and Financial Markets from Universität St. Gallen in Switzerland in 1997

close

Anders Månsson

Chief Executive Officer

mansson@oncoinvent.com

Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.

Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.

close